- Conditions
- Prostate Cancer, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Head and Neck Cancer, Bladder Cancer, Non-small Cell Lung Cancer
- Interventions
- MGA271
- Biological
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 12
- States / cities
- Los Angeles, California • New Haven, Connecticut • Tampa, Florida + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Prostate Cancer
- Interventions
- NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostatic Neoplasm
- Interventions
- 177Lu-PSMA-R2
- Drug
- Lead sponsor
- Advanced Accelerator Applications
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • San Francisco, California • Stanford, California + 6 more
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
- Interventions
- Docetaxel, Lycopene
- Drug · Dietary Supplement
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Zanzalintinib
- Drug
- Lead sponsor
- Pedro Barata, MD, MSc
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- CNS Brain Metastases, Head and Neck Cancer, Lung Cancer, Prostate Cancer, Esophageal Cancer
- Interventions
- PET imaging with CuATSM, PET imaging, PET CuATSM
- Procedure
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Prostate Cancer
- Interventions
- bicalutamide, radiation therapy, placebo
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- Male only
- Enrollment
- 840 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2022
- U.S. locations
- 221
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 168 more
- Conditions
- Prostatic Neoplasms
- Interventions
- Placebo, Dasatinib, Docetaxel, Prednisone
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,930 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 43
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Fayetteville, Arkansas + 35 more
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- 64Cu-SAR-BBN, 67Cu-SAR-BBN
- Drug
- Lead sponsor
- Clarity Pharmaceuticals Ltd
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 6
- States / cities
- Stanford, California • Miami, Florida • Grand Rapids, Michigan + 3 more
- Conditions
- Prostate Adenocarcinoma, Prostate Cancer
- Interventions
- Ga-HBED-iPSMA PET, PET/CT, MRI
- Drug · Diagnostic Test
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Prostate Cancer
- Interventions
- Apalutamide, Placebo, Androgen Deprivation Therapy (ADT)
- Drug
- Lead sponsor
- Aragon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,052 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 39
- States / cities
- Homewood, Alabama • Tucson, Arizona • San Bernardino, California + 36 more
- Conditions
- Breast Cancer, Colorectal Cancer, Prostate Cancer, Head and Neck Cancer, Lung Cancer
- Interventions
- Telephone interview or self report survey.
- Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Cancer
- Interventions
- physiologic testing, study of socioeconomic and demographic variables, evaluation of cancer risk factors, mutation carrier screening, study of high risk factors
- Other · Procedure
- Lead sponsor
- Lawrence Livermore National Laboratory at University of California
- Other
- Eligibility
- 50 Years to 70 Years · Male only
- Enrollment
- 800 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2002
- U.S. locations
- 2
- States / cities
- Livermore, California • Oakland, California
- Conditions
- Advanced Solid Tumors, Adenocarcinoma of the Prostate
- Interventions
- Alisertib, Docetaxel
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • Portland, Oregon • San Antonio, Texas + 1 more
- Conditions
- Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- Interventions
- Cabazitaxel and carboplatin, Lu-PSMA-617
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- TAS0612
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee • Houston, Texas
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Placebo Administration, Urolithin A Supplement
- Procedure · Drug · Dietary Supplement
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Chicago, Illinois • Durham, North Carolina + 1 more
- Conditions
- Androgen Deprivation Therapy, Locally Advanced Prostate Cancer
- Interventions
- Relugolix and Enzalutamide
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Prostatic Neoplasm
- Interventions
- EMPOWER
- Behavioral
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Biochemical Recurrent Prostate Cancer
- Interventions
- Isoflavone
- Dietary Supplement
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 45 Years to 80 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Prostate Adenocarcinoma, Prostate Cancer, High Risk Prostate Cancer
- Interventions
- Enzalutamide, Abiraterone Acetate, Prednisone, Leuprolide Acetate
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Seattle, Washington
- Conditions
- Prostate Cancer
- Interventions
- positron emission tomography, fludeoxyglucose F 18, methionine C 11
- Procedure · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 0 Years to 120 Years · Male only
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Cancer, Kidney Cancer
- Interventions
- High intensity approach, Low intensity approach
- Behavioral
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Chambersburg, Pennsylvania
- Conditions
- Prostate Cancer
- Interventions
- quality-of-life assessment
- Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- Up to 75 Years · Male only
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 13
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Iowa City, Iowa + 10 more